Gentzler R.D.,Northwestern Universityrobert rie Comprehensive Cancer Centerchicago |
Yentz S.E.,Northwestern UniversityChicago |
Johnson M.L.,Northwestern Universityrobert rie Comprehensive Cancer Centerchicago |
Rademaker A.W.,Northwestern Universityrobert rie Comprehensive Cancer Centerchicago |
Patel J.D.,Northwestern Universityrobert rie Comprehensive Cancer Centerchicago
Cancer | Year: 2014
Over the last decade, new cytotoxic treatments and targeted therapies have altered treatment paradigms for patients with metastatic non-small cell lung cancer (NSCLC). We sought to analyze the impact of histology and biomarker selection criteria on outcomes of clinical trials in metastatic NSCLC reported over the last decade at the American Society of Clinical Oncology (ASCO) Annual Meeting. Data were collected from ASCO abstracts of Phase II-IV clinical trials for patients with metastatic NSCLC from 2004-2014. 770 of 2,989 identified metastatic NSCLC category abstracts met selection criteria. Despite a decline in the number of abstracts from 107 to 46 abstracts annually over this period, the proportion of trials with positive progression free survival (PFS) and overall survival (OS) outcomes has increased significantly. Trials with histology selection (6%) or molecular biomarker (15%) criteria were more likely to result in an improvement in PFS than those without selection criteria (21% vs. 8%, p=0.0001 and 31% vs. 10%, p<0.0001, respectively). These data demonstrate profound changes in the clinical trial landscape over the last 10 years with significantly increasing proportion of trials with positive outcomes. These changes are likely attributed to the use of histology and biomarker selection criteria in clinical trial design. ASCO abstracts for NSCLC trials over the last 11 years have shown an increasing rate of positive PFS and OS outcomes. Molecular biomarker and histology selection criteria in trials may account for this increase in positive outcomes. © 2014 American Cancer Society.